Pazenir monotherapy is indicated for the treatment of metastatic breast cancer in adult patients who have failed first-line treatment for metastatic disease and for whom standard, anthracycline containing therapy is not indicated (see section 4.4). Pazenir in combination with gemcitabine is indicated for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas. Pazenir in combination with carboplatin is indicated for the first-line treatment of non-small cell lung cancer in adult patients who are not candidates for potentially curative surgery and/or radiation therapy.
Gilead Sciences, Inc. and MYR GmbH, a German biotechnology company focused on the development and commercialization of therapeutics for the treatment of chronic hepatitis delta virus (HDV).
Baxter International Inc and SuppreMol GmbH announced that Baxter has acquired SuppreMol for EUR 200 million (approximately $225M USD )...
Merck Inc. and Rigontec GmbH announced that Merck will acquire Rigontec. Rigontec is a pioneer in accessing the retinoic acid-inducible...
invendo medical GmbH, a leading developer and distributor of sterile, single-use and robotically-assisted endoscopy products in the field of gastroenterology...
vasopharm GmbH, a privately held biopharmaceutical company focusing on novel therapeutics for the treatment of cerebrovascular diseases, announced that the...
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation under exceptional circumstances for the medicinal product Obiltoxaximab SFL, intended for the treatment or post-exposure prophylaxis of inhalational anthrax.